Sanofi (SNY) Capital Expenditures (2009 - 2021)
Sanofi (SNY) posted Capital Expenditures of -$101.4 million for Q4 2021, up 3.84% sequentially from -$105.4 million in Q4 2020, and up 3.84% YoY from -$97.6 million in Q4 2020.
Sanofi (SNY) Capital Expenditures (2009 - 2021) Analysis & Trends
Sanofi (SNY) has 5 years of Capital Expenditures data on file, last reported at -$101.4 million in Q4 2021.
- Quarterly Capital Expenditures rose 3.84% year-over-year to -$101.4 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $653.3 million (down 66.86% YoY) and the FY2025 annual result came in at $4.1 billion, up 20.63% from the prior year.
- Capital Expenditures improved to -$101.4 million in Q4 2021 per SNY's latest filing, from -$105.4 million in the prior quarter.
- The five-year high for Capital Expenditures was -$90.5 million in Q4 2019, with the low at -$105.4 million in Q4 2020.
- Average Capital Expenditures over 3 years is -$99.1 million, with a median of -$101.4 million recorded in 2021.
- Year-over-year, Capital Expenditures dropped 16.41% in 2020 and rose 3.84% in 2021.
- Sanofi's Capital Expenditures stood at -$90.5 million in 2019, then decreased by 16.41% to -$105.4 million in 2020, then grew by 3.84% to -$101.4 million in 2021.
- Business Quant data shows SNY's Capital Expenditures at -$101.4 million in Q4 2021, -$105.4 million in Q4 2020, and -$90.5 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 2.33 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 265.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -547.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 991.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 712.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 117.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 436.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -346.00 Mn |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -101.36 Mn |
| Dec 31, 2021 | -101.36 Mn |
| Dec 31, 2020 | -105.40 Mn |
| Dec 31, 2020 | -105.40 Mn |
| Dec 31, 2019 | -90.54 Mn |
| Dec 31, 2019 | -90.54 Mn |
| Jun 30, 2013 | 950.59 Mn |
| Jun 30, 2013 | 950.59 Mn |
| Dec 31, 2009 | 1.22 Bn |
| Dec 31, 2009 | 1.22 Bn |